AT-II exerted significant antitumor effects on gastric carcinoma cells by modulating the Akt/ERK signaling pathway, which upregulated the expression level of Bax but downregulated the expression levels of B-cell lymphoma-2 (Bcl-2), p-Akt, and p-ERK compared to those of the control group [90]. This evidence concerns the gene AKT1 and gastric carcinoma.